Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial
Identifieur interne : 003724 ( PascalFrancis/Curation ); précédent : 003723; suivant : 003725Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial
Auteurs : Hisatomi Arima [Australie] ; Craig Anderson [Australie] ; Teruo Omae [Japon] ; LISHENG LIU [République populaire de Chine] ; Christophe Tzourio [France] ; Mark Woodward [États-Unis] ; Stephen Macmahon [Australie] ; Bruce Neal [Australie] ; Anthony Rodgers [Australie] ; John Chalmers [Australie]Source :
- Journal of hypertension [ 0263-6352 ] ; 2010.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Objective To assess the benefits of blood pressure (BP) lowering on vascular events separately for Asian and for Western participants with particular emphasis on stroke subtypes and cardiac outcomes. Methods This is a subsidiary analysis of Perindopril Protection Against Recurrent Stroke Study (PROGRESS), a randomized, placebo-controlled trial that established the benefits of BP lowering in 6105 patients with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, and indapamide for those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). Outcomes are total and cause-specific vascular outcomes. Results The annual rates for total major vascular events were 4.2% in Asian and 5.2% in Western participants. Overall stroke rates were greater in Asian compared to Western participants with proportionally more lacunar infarctions and haemorrhagic strokes in Asians and more cardio-embolic infarctions and large artery infarctions in Western participants. Active treatment reduced BP by 10.3/ 4.6 mmHg in Asian, and by 8.1/3.6 mmHg in Western participants. Among Asian participants there was a 38% [95% confidence interval (CI) 23-49%] reduction in major vascular events compared to a 20% (95% CI 7-31%) reduction in Western participants (P homogeneity = 0.06). Similarly, there were higher relative risk reductions for all other outcomes among Asian participants, but this only reached statistical significance for heart failure and vascular death (P= 0.02 for each). The number needed to treat for major vascular events over 5 years was 15 (95% CI 10-26) in Asian compared to 28 (95% CI 17-94) in Western participants (P homogeneity = 0.09). Conclusions BP lowering reduces the risk of major vascular events, with separately significant reductions, in both Asia and the West.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002862
Links to Exploration step
Pascal:10-0104497Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial</title><author><name sortKey="Arima, Hisatomi" sort="Arima, Hisatomi" uniqKey="Arima H" first="Hisatomi" last="Arima">Hisatomi Arima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Anderson, Craig" sort="Anderson, Craig" uniqKey="Anderson C" first="Craig" last="Anderson">Craig Anderson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Omae, Teruo" sort="Omae, Teruo" uniqKey="Omae T" first="Teruo" last="Omae">Teruo Omae</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Cardiovascular Center</s1><s2>Suita</s2><s3>JPN</s3><sZ>3 aut.</sZ></inist:fA14><country>Japon</country></affiliation></author><author><name sortKey="Lisheng Liu" sort="Lisheng Liu" uniqKey="Lisheng Liu" last="Lisheng Liu">LISHENG LIU</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Hypertension, Fu Wai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences</s1><s2>Beijing</s2><s3>CHN</s3><sZ>4 aut.</sZ></inist:fA14><country>République populaire de Chine</country></affiliation></author><author><name sortKey="Tzourio, Christophe" sort="Tzourio, Christophe" uniqKey="Tzourio C" first="Christophe" last="Tzourio">Christophe Tzourio</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>INSERM U708 and the Department of Neurology, Hôpital Lariboisière</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Sinai School of Medicine</s1><s2>New York</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Macmahon, Stephen" sort="Macmahon, Stephen" uniqKey="Macmahon S" first="Stephen" last="Macmahon">Stephen Macmahon</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Rodgers, Anthony" sort="Rodgers, Anthony" uniqKey="Rodgers A" first="Anthony" last="Rodgers">Anthony Rodgers</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">10-0104497</idno><date when="2010">2010</date><idno type="stanalyst">PASCAL 10-0104497 INIST</idno><idno type="RBID">Pascal:10-0104497</idno><idno type="wicri:Area/PascalFrancis/Corpus">002862</idno><idno type="wicri:Area/PascalFrancis/Curation">003724</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial</title><author><name sortKey="Arima, Hisatomi" sort="Arima, Hisatomi" uniqKey="Arima H" first="Hisatomi" last="Arima">Hisatomi Arima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Anderson, Craig" sort="Anderson, Craig" uniqKey="Anderson C" first="Craig" last="Anderson">Craig Anderson</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Omae, Teruo" sort="Omae, Teruo" uniqKey="Omae T" first="Teruo" last="Omae">Teruo Omae</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>National Cardiovascular Center</s1><s2>Suita</s2><s3>JPN</s3><sZ>3 aut.</sZ></inist:fA14><country>Japon</country></affiliation></author><author><name sortKey="Lisheng Liu" sort="Lisheng Liu" uniqKey="Lisheng Liu" last="Lisheng Liu">LISHENG LIU</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Hypertension, Fu Wai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences</s1><s2>Beijing</s2><s3>CHN</s3><sZ>4 aut.</sZ></inist:fA14><country>République populaire de Chine</country></affiliation></author><author><name sortKey="Tzourio, Christophe" sort="Tzourio, Christophe" uniqKey="Tzourio C" first="Christophe" last="Tzourio">Christophe Tzourio</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>INSERM U708 and the Department of Neurology, Hôpital Lariboisière</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Woodward, Mark" sort="Woodward, Mark" uniqKey="Woodward M" first="Mark" last="Woodward">Mark Woodward</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Mount Sinai School of Medicine</s1><s2>New York</s2><s3>USA</s3><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country></affiliation></author><author><name sortKey="Macmahon, Stephen" sort="Macmahon, Stephen" uniqKey="Macmahon S" first="Stephen" last="Macmahon">Stephen Macmahon</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Neal, Bruce" sort="Neal, Bruce" uniqKey="Neal B" first="Bruce" last="Neal">Bruce Neal</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Rodgers, Anthony" sort="Rodgers, Anthony" uniqKey="Rodgers A" first="Anthony" last="Rodgers">Anthony Rodgers</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Chalmers, John" sort="Chalmers, John" uniqKey="Chalmers J" first="John" last="Chalmers">John Chalmers</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author></analytic><series><title level="j" type="main">Journal of hypertension</title><title level="j" type="abbreviated">J. hypertens.</title><idno type="ISSN">0263-6352</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of hypertension</title><title level="j" type="abbreviated">J. hypertens.</title><idno type="ISSN">0263-6352</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antihypertensive agent</term><term>Arterial pressure</term><term>Blood pressure</term><term>Cardiovascular disease</term><term>Cerebrovascular disease</term><term>Diuretic</term><term>Hypertension</term><term>Indapamide</term><term>Perindopril</term><term>Stroke</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Pathologie cérébrovasculaire</term><term>Accident cérébrovasculaire</term><term>Pathologie de l'appareil circulatoire</term><term>Périndopril</term><term>Pression artérielle</term><term>Pression sanguine</term><term>Indapamide</term><term>Hypertension artérielle</term><term>Antihypertenseur</term><term>Diurétique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective To assess the benefits of blood pressure (BP) lowering on vascular events separately for Asian and for Western participants with particular emphasis on stroke subtypes and cardiac outcomes. Methods This is a subsidiary analysis of Perindopril Protection Against Recurrent Stroke Study (PROGRESS), a randomized, placebo-controlled trial that established the benefits of BP lowering in 6105 patients with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, and indapamide for those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). Outcomes are total and cause-specific vascular outcomes. Results The annual rates for total major vascular events were 4.2% in Asian and 5.2% in Western participants. Overall stroke rates were greater in Asian compared to Western participants with proportionally more lacunar infarctions and haemorrhagic strokes in Asians and more cardio-embolic infarctions and large artery infarctions in Western participants. Active treatment reduced BP by 10.3/ 4.6 mmHg in Asian, and by 8.1/3.6 mmHg in Western participants. Among Asian participants there was a 38% [95% confidence interval (CI) 23-49%] reduction in major vascular events compared to a 20% (95% CI 7-31%) reduction in Western participants (P homogeneity = 0.06). Similarly, there were higher relative risk reductions for all other outcomes among Asian participants, but this only reached statistical significance for heart failure and vascular death (P= 0.02 for each). The number needed to treat for major vascular events over 5 years was 15 (95% CI 10-26) in Asian compared to 28 (95% CI 17-94) in Western participants (P homogeneity = 0.09). Conclusions BP lowering reduces the risk of major vascular events, with separately significant reductions, in both Asia and the West.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0263-6352</s0></fA01><fA02 i1="01"><s0>JOHYD3</s0></fA02><fA03 i2="1"><s0>J. hypertens.</s0></fA03><fA05><s2>28</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial</s1></fA08><fA11 i1="01" i2="1"><s1>ARIMA (Hisatomi)</s1></fA11><fA11 i1="02" i2="1"><s1>ANDERSON (Craig)</s1></fA11><fA11 i1="03" i2="1"><s1>OMAE (Teruo)</s1></fA11><fA11 i1="04" i2="1"><s1>LISHENG LIU</s1></fA11><fA11 i1="05" i2="1"><s1>TZOURIO (Christophe)</s1></fA11><fA11 i1="06" i2="1"><s1>WOODWARD (Mark)</s1></fA11><fA11 i1="07" i2="1"><s1>MACMAHON (Stephen)</s1></fA11><fA11 i1="08" i2="1"><s1>NEAL (Bruce)</s1></fA11><fA11 i1="09" i2="1"><s1>RODGERS (Anthony)</s1></fA11><fA11 i1="10" i2="1"><s1>CHALMERS (John)</s1></fA11><fA14 i1="01"><s1>The George Institute for International Health, the University of Sydney and the Royal Prince Alfred Hospital</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="02"><s1>National Cardiovascular Center</s1><s2>Suita</s2><s3>JPN</s3><sZ>3 aut.</sZ></fA14><fA14 i1="03"><s1>Division of Hypertension, Fu Wai Hospital and Cardiovascular Institute, Chinese Academy of Medical Sciences</s1><s2>Beijing</s2><s3>CHN</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>INSERM U708 and the Department of Neurology, Hôpital Lariboisière</s1><s2>Paris</s2><s3>FRA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Mount Sinai School of Medicine</s1><s2>New York</s2><s3>USA</s3><sZ>6 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>PROGRESS Collaborative Group</s1><s3>INC</s3></fA17><fA20><s1>395-400</s1></fA20><fA21><s1>2010</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20680</s2><s5>354000189585390280</s5></fA43><fA44><s0>0000</s0><s1>© 2010 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>19 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>10-0104497</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of hypertension</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Objective To assess the benefits of blood pressure (BP) lowering on vascular events separately for Asian and for Western participants with particular emphasis on stroke subtypes and cardiac outcomes. Methods This is a subsidiary analysis of Perindopril Protection Against Recurrent Stroke Study (PROGRESS), a randomized, placebo-controlled trial that established the benefits of BP lowering in 6105 patients with cerebrovascular disease, randomly assigned to either active treatment (perindopril for all, and indapamide for those with neither an indication for, nor a contraindication to, a diuretic) or placebo(s). Outcomes are total and cause-specific vascular outcomes. Results The annual rates for total major vascular events were 4.2% in Asian and 5.2% in Western participants. Overall stroke rates were greater in Asian compared to Western participants with proportionally more lacunar infarctions and haemorrhagic strokes in Asians and more cardio-embolic infarctions and large artery infarctions in Western participants. Active treatment reduced BP by 10.3/ 4.6 mmHg in Asian, and by 8.1/3.6 mmHg in Western participants. Among Asian participants there was a 38% [95% confidence interval (CI) 23-49%] reduction in major vascular events compared to a 20% (95% CI 7-31%) reduction in Western participants (P homogeneity = 0.06). Similarly, there were higher relative risk reductions for all other outcomes among Asian participants, but this only reached statistical significance for heart failure and vascular death (P= 0.02 for each). The number needed to treat for major vascular events over 5 years was 15 (95% CI 10-26) in Asian compared to 28 (95% CI 17-94) in Western participants (P homogeneity = 0.09). Conclusions BP lowering reduces the risk of major vascular events, with separately significant reductions, in both Asia and the West.</s0></fC01><fC02 i1="01" i2="X"><s0>002B12B05</s0></fC02><fC02 i1="02" i2="X"><s0>002A22D</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Pathologie cérébrovasculaire</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Cerebrovascular disease</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Vaso sanguíneo encéfalo patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Accident cérébrovasculaire</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Stroke</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Accidente cerebrovascular</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Périndopril</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Perindopril</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Perindopril</s0><s2>NK</s2><s2>FR</s2><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Pression artérielle</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Arterial pressure</s0><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Presión arterial</s0><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Pression sanguine</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Blood pressure</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Presión sanguínea</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Indapamide</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Indapamide</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Indapamida</s0><s2>NK</s2><s2>FR</s2><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Hypertension artérielle</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Hypertension</s0><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Hipertensión arterial</s0><s5>13</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Antihypertenseur</s0><s5>78</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Antihypertensive agent</s0><s5>78</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Antihipertensivo</s0><s5>78</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Diurétique</s0><s5>79</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Diuretic</s0><s5>79</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Diurético</s0><s5>79</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Inhibiteur angiotensin converting enzyme</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>ACE inhibitor</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Inhibidor angiotensin converting enzyme</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzyme inhibitor</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Inhibidor enzima</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Peptidyl-dipeptidase A</s0><s2>FE</s2><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Peptidyl-dipeptidase A</s0><s2>FE</s2><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Peptidyl-dipeptidase A</s0><s2>FE</s2><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Peptidyl-dipeptidases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Peptidyl-dipeptidases</s0><s2>FE</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Peptidyl-dipeptidases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Peptidases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Hydrolases</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>40</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0><s5>41</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>41</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0><s5>42</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>42</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>42</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Dérivé de l'indole</s0><s5>43</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Indole derivatives</s0><s5>43</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Indol derivado</s0><s5>43</s5></fC07><fC07 i1="12" i2="X" l="FRE"><s0>Sulfamides</s0><s5>44</s5></fC07><fC07 i1="12" i2="X" l="ENG"><s0>Sulfonamides</s0><s5>44</s5></fC07><fC07 i1="12" i2="X" l="SPA"><s0>Sulfamidas</s0><s5>44</s5></fC07><fC07 i1="13" i2="X" l="FRE"><s0>Thiazide</s0><s5>45</s5></fC07><fC07 i1="13" i2="X" l="ENG"><s0>Thiazide</s0><s5>45</s5></fC07><fC07 i1="13" i2="X" l="SPA"><s0>Tiazida</s0><s5>45</s5></fC07><fC07 i1="14" i2="X" l="FRE"><s0>Pathologie des vaisseaux sanguins</s0><s5>46</s5></fC07><fC07 i1="14" i2="X" l="ENG"><s0>Vascular disease</s0><s5>46</s5></fC07><fC07 i1="14" i2="X" l="SPA"><s0>Vaso sanguíneo patología</s0><s5>46</s5></fC07><fN21><s1>067</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003724 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003724 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:10-0104497
|texte= Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial
}}
| This area was generated with Dilib version V0.6.33. |  |